Application YC di Kernal Biologics
Kernal Biologics ha partecipato a Y Combinator nel batch Summer 2020 come azienda Healthcare. Sotto: cosa fa l'azienda, chi l'ha fondata e la sua application a YC, ricostruita domanda per domanda nel form reale di YC.
- Batch YC
- Summer 2020
- Settore
- HealthcareTherapeutics
- Dimensione team
- 20
- Stato
- Active
- Lanciata
- 2020
Founder
Yusuf ErkulFounder
Jeff OzdemirFounder
Burak YILMAZFounder
Cosa fa Kernal Biologics
Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).
Application YC di Kernal Biologics, ricostruita
Domanda per Y Combinator
Kernal Biologics, batch Summer 2020. Le vere domande del form, risposte da dati pubblici.
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
Kernal Biologics
mRNA 2.0 therapies targeting specific cells
We're building selective mRNA-LNP immunotherapies that deliver mRNA precisely to specific immune cells. Our lead program, KR-402, targets T cells to program CAR-T therapies directly in the body and can deplete B cells within a week. This lets us treat cancer and autoimmune diseases with fewer off-target effects than current mRNA approaches.
We live in Cambridge, MA, and Kernal is based there. After YC, we'd remain in Cambridge because that's where our team, science, and investors are concentrated.
Cambridge is a biotech hub with access to top academic talent and proximity to investors, which is critical for developing complex mRNA therapeutics. Being near MIT and Harvard also helps us recruit and collaborate on cutting-edge science.
21 risposte in più nell'application completa
Founders, Progress, Idea, Equity, Curious, Batch Preference sono nella versione completa. Crea un account gratuito per aprirla in YC Insights, accanto a ogni altro batch YC.
Domande Frequenti
Questa è l'application YC reale di Kernal Biologics?
No. Y Combinator mantiene private le application inviate. Questa è una ricostruzione: le domande del form YC reale, a cui si è risposto usando i dati pubblici di Kernal Biologics (note di lancio, background dei founder, descrizione del prodotto). Mostra come un'azienda come Kernal Biologics si presenterebbe a YC, non il testo che hanno inviato.
A quale batch YC apparteneva Kernal Biologics?
Kernal Biologics apparteneva al batch Summer 2020 di Y Combinator.
Chi ha fondato Kernal Biologics?
Kernal Biologics è stato fondato da Yusuf Erkul, Jeff Ozdemir, Burak YILMAZ.
Cosa fa Kernal Biologics?
Kernal is creating mRNA 2.0 therapies that work in specific cells
Come leggo la ricostruzione completa della application?
Crea un account Round Funded gratuito. La versione completa di 26 risposte della application di Kernal Biologics, e di ogni altro batch YC, è in YC Insights.
Più startup YC come Kernal Biologics
